BioCryst Pharmaceuticals (NASDAQ:BCRX) Raised to “Strong-Buy” at StockNews.com

BioCryst Pharmaceuticals (NASDAQ:BCRX) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Tuesday.

Several other equities analysts also recently issued reports on BCRX. Needham & Company LLC upped their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. raised their price target on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Tuesday. Evercore ISI boosted their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Wedbush initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 target price on the stock. Finally, Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They issued an “overweight” rating and a $20.00 price target for the company. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $16.56.

BioCryst Pharmaceuticals Trading Down 1.9 %

Shares of NASDAQ BCRX opened at $10.08 on Tuesday. BioCryst Pharmaceuticals has a 12-month low of $5.04 and a 12-month high of $11.11. The stock has a market cap of $2.11 billion, a P/E ratio of -16.52 and a beta of 1.08. The business’s fifty day simple moving average is $7.81 and its 200-day simple moving average is $7.86.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. The business’s quarterly revenue was up 40.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.28 earnings per share. On average, equities analysts forecast that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Mackenzie Financial Corp boosted its position in shares of BioCryst Pharmaceuticals by 37.3% during the 1st quarter. Mackenzie Financial Corp now owns 116,258 shares of the biotechnology company’s stock worth $872,000 after purchasing an additional 31,596 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of BioCryst Pharmaceuticals in the first quarter valued at about $125,000. Y Intercept Hong Kong Ltd boosted its holdings in BioCryst Pharmaceuticals by 106.7% during the first quarter. Y Intercept Hong Kong Ltd now owns 141,865 shares of the biotechnology company’s stock worth $1,064,000 after buying an additional 73,242 shares in the last quarter. Allianz Asset Management GmbH grew its position in BioCryst Pharmaceuticals by 9.6% during the first quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company’s stock worth $103,000 after buying an additional 1,200 shares during the period. Finally, Hussman Strategic Advisors Inc. purchased a new position in BioCryst Pharmaceuticals in the first quarter valued at about $2,362,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.